Below are MBC trials that have been added to BreastCancerTrials.org (BCT) in the last month. These trials can also be found on Metastatic Trial Search (MTS)
All MBC
- The Targeted Therapy LY3475070 Alone or With Pembrolizumab in Advanced Breast Cancer
- IMX-110 for Advanced Breast Cancer
Triple-Negative
- LY3435151 Alone or With Pembrolizumab in Advanced Triple Negative Breast Cancer
- Talazoparib in Women With Metastatic TNBC or HR+, HER2- Breast Cancer With A Somatic (Not Inherited) BRCA1/2 Mutation
HR Positive (HR+)
- Immunotherapy DF1001 Alone or With Keytruda® for IHC HER2 1+, 2+ or 3+ Metastatic Breast Cancer
- Niraparib and Herceptin in Women With Metastatic HER2+ Breast Cancer
- LY3484356 Alone or With Abemaciclib in Advanced ER+, HER2- Breast Cancer
- ZN-C5 for Stage I, II, III, and IV ER+, HER2- Breast Cancer
- Your Hormone Therapy & GMI-1359 in Hormone Positive Metastatic Breast Cancer
- Talazoparib in Women With Metastatic TNBC or HR+, HER2- Breast Cancer With A Somatic (Not Inherited) BRCA1/2 Mutation
BRCA Positive
- NMS-03305293 in Advanced HER2 Negative Breast Cancer in People with a Hereditary BRCA Mutation
- PARP Inhibitor Rucaparib in Advanced Breast Cancer That Tests Positive for BRCA or Other Mutations
- Talazoparib in Women With Metastatic TNBC or HR+, HER2- Breast Cancer With A Somatic (Not Inherited) BRCA1/2 Mutation
Mutation Specific
- BDTX-189 in Metastatic Breast Cancer That Tests Positive for Certain Markers (Mutations)
- eFT226 in Advanced Breast Cancer That Tests Positive for HER2, ERBB3, FGFR1, FGFR2, or KRAS Mutations
Use Metastatic Trial Search to find all metastatic breast cancer trials that are right for you.
